Biotech financing & business development
TIM MULLER President SCIENTEX - from science to stock exchange
Pharma PhD, MS finance Sorbonne, MS management, 10 years healthcare PE investor, 18 years busdev with IPO and M&A track-record inside my 120 sell & buy side deals through 38 EU & US mandates
Good morning
Former researcher in medicinal chemistry for Servier on CNS and diabetes mellitus, former venture capitalist in biotech during 10 years for Sofimac Partners (now UI) and CDC Innovation (then BPI France now LBO France) and venture partner (Go Capital...), then business developer in healthcare/life sciences since 2006, I have built my track record through +120 various deals (sell & buy side, financing, partnering, licensing, IPO, M&A, M&S ...) including the IPO of Crossject in 2014, through + 38 US, UK and EU international mandates. I am focused on supporting young fast growing companies: transforming startups into SMEs. I am currently looking for a new startup to support on a day to day basis.
In order to have a pragmatic, suitable and scalable offer for startups, my holding company SCIENTEX is offering a cost effective alternative to my clients (biotech and/or pharma and/or and/or medtech) to support their commercial, business, partnership, financial and corporate operations. In summary, I am supporting operationally CFO and CBO functions for the full cost of a 50K€ FTE and limit my activity to 2 clients max for the 2 SCIENTEX partners if we are shared, but we can be dedicated as we did for Crossject for example. In addition, SCIENTEX supports is always eligible for EXPORT subsidies and grants (example 75K€ by the Normandy Region for 24 months).
Here is the link for my brochure:
Looking forward to hearing from you
Kindest regards
Tim Muller, Ph.D.
President
SCIENTEX Group
Best European business development company in healthcare since 2018
Villa GOADIK, 49 avenue du littoral 44380 PORNICHET- FRANCE
Join my +75K linkedin contacts, connections & followers?on :??fr.linkedin.com/in/timotheemuller